Pfizer Inc (PFE)

$25.68 -0.37 (-1.42%)
Market Cap 150.92B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.67
Forward PE 8.90
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 38,903,300
Avg Vol 38,630,813
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 4%
Beta 0.35
Analysts Sell
Price Target $29.20

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
SentinelStocks
SentinelStocks May. 9 at 7:32 AM
$PFE Pharmaceutical company with diversified healthcare exposure and strong cash-flow generation
0 · Reply
JBS_84
JBS_84 May. 9 at 5:03 AM
$PFE For those interested this will be turning around bullish and it won't be because of hantavirus.
1 · Reply
DragonAlgoTrades
DragonAlgoTrades May. 9 at 4:55 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-05-15 | Strike: $25.50 | Type: PUT Option Plan (premium): Entry: $0.22 Stop: $0.16 TP1: $0.29 TP2: $0.38 TP3: $0.54 🔗 https://dragonalgo.com
0 · Reply
jdubh22a
jdubh22a May. 9 at 3:03 AM
$PFE we are trending , lets goooo
0 · Reply
LoneBroker
LoneBroker May. 9 at 2:28 AM
$PFE $25.68 🐻 • RSI 35.22 • ATR% 2.30 • vol↓ Support & Resistance — UPDATED 2026-05-08 3 Days | Support: $25.60 – $25.60 | Resistance: $26.72 – $26.72 5 Days | Support: $25.60 – $25.60 | Resistance: $26.75 – $26.75 7 Days | Support: $25.60 – $25.60 | Resistance: $26.91 – $26.91 20 Days | Support: $25.60 – $25.60 | Resistance: $27.84 – $27.84 60 Days | Support: $25.60 – $25.60 | Resistance: $28.75 – $28.75 100 Days | Support: $24.83 – $24.83 | Resistance: $28.75 – $28.75 200 Days | Support: $23.11 – $23.11 | Resistance: $28.75 – $28.75 Momentum leans bearish with RSI at 35.22. Volatility sits at 2.30% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. ----------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT
0 · Reply
jdubh22a
jdubh22a May. 9 at 2:09 AM
$PFE
1 · Reply
pasuny
pasuny May. 9 at 2:08 AM
$PFE Miserable, fraudulent company selling harmful drugs, deceiving people with fake news. My MAGA president will take down this evil company with a Tomahawk!
1 · Reply
TraderJoe65
TraderJoe65 May. 9 at 1:40 AM
$ABT with Markary out looks like all the Bio stocks should get fresh looks again and Abbott Labs looks like it suffered more than most. $MRNA $REPL $PFE
1 · Reply
Rizzy234
Rizzy234 May. 9 at 1:32 AM
$PFE why this not pumping?
1 · Reply
mikesterz7
mikesterz7 May. 9 at 1:15 AM
$NVAX $PFE $JNJ $MRNA $AZN The race to get a vaccine 😆🤣🤣🤣🤣
1 · Reply
Latest News on PFE
Mixed options sentiment in Pfizer with shares down 1.52%

2026-05-08T22:49:53.000Z - 10 hours ago

Mixed options sentiment in Pfizer with shares down 1.52%

Mixed options sentiment in Pfizer with shares up 0.28%

2026-05-07T01:58:20.000Z - 2 days ago

Mixed options sentiment in Pfizer with shares up 0.28%

Pfizer sees high-single-digit annual revenue increases 2029-2033, WSJ reports

2026-05-05T20:09:06.000Z - 3 days ago

Pfizer sees high-single-digit annual revenue increases 2029-2033, WSJ reports

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 3 days ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 3 days ago

Pfizer CEO on AI-designed molecule, and race to use new tech

BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports

2026-05-05T15:41:20.000Z - 3 days ago

BioNTech to cut up to 1,860 jobs, close multiple global sites, Reuters reports

BNTX

3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 3 days ago

3 Dividend Stocks for May 2026

SYY WSO

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 3 days ago

Pfizer Earnings Call Transcript: Q1 2026

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 3 days ago

Pfizer Posts Better-Than-Expected Revenue, Profit

PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook

2026-05-05T11:42:00.000Z - 3 days ago

PFE Earnings: Pfizer Stock Rises on Q1 Beat despite Lower 2026 Sales Outlook

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:23 AM EDT - 3 days ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:06 AM EDT - 3 days ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

Options Volatility and Implied Earnings Moves Today, May 05, 2026

2026-05-05T11:05:22.000Z - 3 days ago

Options Volatility and Implied Earnings Moves Today, May 05, 2026

AMD BBAI ET LCID MSTR OXY PYPL

Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 3 days ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:55 AM EDT - 3 days ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:51 AM EDT - 3 days ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

Pfizer reports Q1 adjusted EPS 75c, consensus 72c

2026-05-05T10:48:34.000Z - 3 days ago

Pfizer reports Q1 adjusted EPS 75c, consensus 72c

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.96

2026-05-05T10:48:19.000Z - 3 days ago

Pfizer backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.96

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 5, 2026, 6:45 AM EDT - 3 days ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

Notable companies reporting before tomorrow’s open

2026-05-04T18:50:45.000Z - 4 days ago

Notable companies reporting before tomorrow’s open

ADM BUD CMI DD ETN FISV GFS

Options Volatility and Implied Earnings Moves This Week, May 04 – May 07, 2026

2026-05-04T11:00:58.000Z - 4 days ago

Options Volatility and Implied Earnings Moves This Week, May 04 – May 07, 2026

ABNB AMD ANET ARM BBAI COIN CVS

Pfizer Reports Q1 Earnings Tomorrow. What Shareholders Should Expect.

2026-05-04T10:43:31.000Z - 4 days ago

Pfizer Reports Q1 Earnings Tomorrow. What Shareholders Should Expect.

Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC

2026-05-01T16:51:08.000Z - 7 days ago

Arvinas announces FDA approval of VEPPANU for ESR1m, ER+/HER2- ABC

ARVN

US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 7 days ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Pfizer's blood cancer drug meets main goal in late-stage trial

Apr 29, 2026, 7:42 AM EDT - 9 days ago

Pfizer's blood cancer drug meets main goal in late-stage trial

Pfizer reports ‘positive’ results from Phase 3 MagnetisMM-5 study

2026-04-29T11:16:25.000Z - 9 days ago

Pfizer reports ‘positive’ results from Phase 3 MagnetisMM-5 study

Pfizer price target raised to $27 from $26 at Citi

2026-04-29T10:59:57.000Z - 9 days ago

Pfizer price target raised to $27 from $26 at Citi

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Apr 29, 2026, 6:45 AM EDT - 9 days ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Apr 28, 2026, 10:41 AM EDT - 10 days ago

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 28, 2026, 10:17 AM EDT - 10 days ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

Apr 24, 2026, 8:36 AM EDT - 14 days ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

BMY

Pfizer Transcript: AGM 2026

Apr 23, 2026, 9:00 AM EDT - 15 days ago

Pfizer Transcript: AGM 2026

Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 4:45 PM EDT - 16 days ago

Pfizer Declares Second-Quarter 2026 Dividend

Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 22, 2026, 5:18 AM EDT - 16 days ago

Pfizer GLP-1 weight loss drug available for pre-order in China

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Apr 21, 2026, 11:51 AM EDT - 17 days ago

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

Apr 20, 2026, 3:05 PM EDT - 18 days ago

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Apr 20, 2026, 6:45 AM EDT - 18 days ago

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

The Big 3: PFE, V, SYF

Apr 16, 2026, 1:01 PM EDT - 22 days ago

The Big 3: PFE, V, SYF

SYF V

Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 10, 2026, 11:00 PM EDT - 4 weeks ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 9, 2026, 10:00 AM EDT - 4 weeks ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 5 weeks ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 5 weeks ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 5 weeks ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 5 weeks ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 6 weeks ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 6 weeks ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 6 weeks ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 6 weeks ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 6 weeks ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 6 weeks ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 6 weeks ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 7 weeks ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 7 weeks ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 7 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 7 weeks ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 7 weeks ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 2 months ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 2 months ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 2 months ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 2 months ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 2 months ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 2 months ago

Pfizer CEO flags issues with FDA's vaccine leadership

Pfizer Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 2 months ago

Pfizer Transcript: TD Cowen 46th Annual Health Care Conference

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 2 months ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 2 months ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 2 months ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

SentinelStocks
SentinelStocks May. 9 at 7:32 AM
$PFE Pharmaceutical company with diversified healthcare exposure and strong cash-flow generation
0 · Reply
JBS_84
JBS_84 May. 9 at 5:03 AM
$PFE For those interested this will be turning around bullish and it won't be because of hantavirus.
1 · Reply
DragonAlgoTrades
DragonAlgoTrades May. 9 at 4:55 AM
🐉 $PFE PUT — DragonAlgo® Signal Contract: PFE PUT Expiry: 2026-05-15 | Strike: $25.50 | Type: PUT Option Plan (premium): Entry: $0.22 Stop: $0.16 TP1: $0.29 TP2: $0.38 TP3: $0.54 🔗 https://dragonalgo.com
0 · Reply
jdubh22a
jdubh22a May. 9 at 3:03 AM
$PFE we are trending , lets goooo
0 · Reply
LoneBroker
LoneBroker May. 9 at 2:28 AM
$PFE $25.68 🐻 • RSI 35.22 • ATR% 2.30 • vol↓ Support & Resistance — UPDATED 2026-05-08 3 Days | Support: $25.60 – $25.60 | Resistance: $26.72 – $26.72 5 Days | Support: $25.60 – $25.60 | Resistance: $26.75 – $26.75 7 Days | Support: $25.60 – $25.60 | Resistance: $26.91 – $26.91 20 Days | Support: $25.60 – $25.60 | Resistance: $27.84 – $27.84 60 Days | Support: $25.60 – $25.60 | Resistance: $28.75 – $28.75 100 Days | Support: $24.83 – $24.83 | Resistance: $28.75 – $28.75 200 Days | Support: $23.11 – $23.11 | Resistance: $28.75 – $28.75 Momentum leans bearish with RSI at 35.22. Volatility sits at 2.30% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. ----------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT
0 · Reply
jdubh22a
jdubh22a May. 9 at 2:09 AM
$PFE
1 · Reply
pasuny
pasuny May. 9 at 2:08 AM
$PFE Miserable, fraudulent company selling harmful drugs, deceiving people with fake news. My MAGA president will take down this evil company with a Tomahawk!
1 · Reply
TraderJoe65
TraderJoe65 May. 9 at 1:40 AM
$ABT with Markary out looks like all the Bio stocks should get fresh looks again and Abbott Labs looks like it suffered more than most. $MRNA $REPL $PFE
1 · Reply
Rizzy234
Rizzy234 May. 9 at 1:32 AM
$PFE why this not pumping?
1 · Reply
mikesterz7
mikesterz7 May. 9 at 1:15 AM
$NVAX $PFE $JNJ $MRNA $AZN The race to get a vaccine 😆🤣🤣🤣🤣
1 · Reply
sam92
sam92 May. 8 at 11:11 PM
$PFE Hanavirus just one more reason to load up on PFE.
1 · Reply
TheUnmaker
TheUnmaker May. 8 at 11:00 PM
$TNXP We closed over the 55 EMA on the daily frame. This is getting ready to explode soon. Keep buying the dips! Institutions keep loading. They know this is a $50+ stock in the short term and higher if you hold longer. BlackRock, Vanguard just to name two. Big things coming! $PFE $PG $JNJ $LLY
1 · Reply
pasuny
pasuny May. 8 at 10:43 PM
$PFE Miserable company with the most stupid fuckin CEO in human history. Resign already!!!! No vision, no plan, very low IQ slow man. This dirty scam drug company has been doing nothing but sinking for the past 5 years! Disgusting, makes me puke!
1 · Reply
SeriouslyWhy
SeriouslyWhy May. 8 at 10:27 PM
$PFE I love how they take the div on ex and also take it again when they pay every fucking time
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 May. 8 at 10:12 PM
$PFE - Totally tubular, surf’s… down
0 · Reply
want2brich
want2brich May. 8 at 10:10 PM
$PFE in some calls 5/15 exp. Just in case more headlines drop over the weekend about new virus
0 · Reply
TheUnmaker
TheUnmaker May. 8 at 10:05 PM
$TNXP Keep buying! MOON SOON!! I'm glad to have added more today and I have open orders in the AH! $PFE $PG $LLY $JNJ
0 · Reply
GroovyTurtle
GroovyTurtle May. 8 at 10:00 PM
$PFE Nice dip. Over 36 MILLION shares were traded. Someone bought.
1 · Reply
buck_7779
buck_7779 May. 8 at 9:57 PM
$PFE why isn’t this up with several of the other pharmaceuticals??☹️
1 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm May. 8 at 9:55 PM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names . $DE $ARM $PFE $NVO
0 · Reply
Tiger65
Tiger65 May. 8 at 9:33 PM
$PFE I’m out again, that was quick. I thought it had found a bottom yesterday. Maybe it has today, but I won’t bet my ass on that.
1 · Reply
F_I_R_E_
F_I_R_E_ May. 8 at 9:10 PM
$META people are addicted to social media and drugs $PFE , but these stocks won’t move up 🤷🏾‍♂️
0 · Reply